Severe asthma and COVID-19: lessons from the first wave

Patrucco, Filippo; Benfante, Alida; Villa, Elisa; Principe, Stefania; Scichilone, Nicola; Solidoro, Paolo

doi:10.1080/02770903.2020.1861622

Cited by 10 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Despite concerns that asthma could be a risk factor for severe COVID-19 disease and that COVID-19 might increase the disease burden of asthma, reports suggest that asthma was not a significant risk factor for severe COVID-19 and that COVID-19-related recommendations for social distancing and exposure avoidance may have reduced the incidence of asthma exacerbations in both adults and children. [5][6][7][8] Patients with SA generally have regular physician visits to monitor their disease control and may have experienced restricted access to healthcare as a result of distancing efforts during the pandemic. 9 The impact of the COVID-19 pandemic on the longitudinal incidence of exacerbations and hospitalizations in adults with SA in the US has not been well-described.…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

Moore¹,

Ledford²,

Carstens³

et al. 2022

JAA

View full text Add to dashboard Cite

Purpose Patients with severe asthma (SA) are at an increased risk of asthma-related hospitalizations and exacerbations. Despite concerns that COVID-19 circulation would increase exacerbations of SA, anecdotal reports suggest that social distancing and exposure avoidance may have led to reduced exacerbations. Patients and methods CHRONICLE is an ongoing noninterventional observational study of 3100 subspecialist-treated patients with SA. Eligible adults (≥ 18 years of age) have (1) current use of monoclonal antibody (ie, biologic) therapy for SA, (2) use of maintenance systemic corticosteroids (mSCS) or other systemic immunosuppressants for ≥ 50% of the prior 12 months for SA, or (3) persistently uncontrolled asthma while treated with high-dosage inhaled corticosteroids with additional controllers. For enrolled patients, electronic medical records were reviewed to record all exacerbations and asthma-related hospitalizations. Descriptive analyses were conducted of the monthly incidence of exacerbations, exacerbation-related visits to the emergency department (ED), and asthma hospitalizations from July 2018 through July 2021. Results Exacerbations, exacerbation-related ED visits, and hospitalizations decreased since April 2020. Exacerbations in 2020 were 20% to 52% lower in April through August relative to the same months in 2019. Exacerbations remained lower than the prior year through May 2021. Similar results were observed by United States (US) census region, with an earlier decrease in exacerbation rates in the western US versus other regions. Across all months, exacerbation rates were lower among biologic recipients. Conclusion In a clinical cohort of subspecialist-treated patients with SA, there was a meaningful reduction in exacerbations, exacerbation-related ED visits, and asthma hospitalizations following COVID-19–related stay-at-home orders and social distancing recommendations. Reasons for these reductions are likely multifactorial, including reduced viral infections due to less social contact and altered patient behavior.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

Moore¹,

Ledford²,

Carstens³

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…Initially, patients with chronic lung disease were enlisted as a high risk group, based on the presumption that viral infections may exacerbate respiratory diseases 10 . The US Centers for Disease Control and Prevention stated that 'people with moderate to severe asthma may be at higher risk of getting very sick from COVID-19.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

Sciberras¹,

Gouder²,

Montefort³

2021

Pneumon

View full text Add to dashboard Cite

INTRODUCTION SARS-CoV-2 was identified as the causative agent of the COVID-19 pandemic, which has been the focus of extensive research for over a year. Asthmatics were listed as a high-risk group for susceptibility to SARS-CoV-2. Several hypotheses have been proposed regarding protective factors in asthmatics, amongst which were the role of biological agents. One such agent is omalizumab, an IgE inhibitor, which is currently the only biological agent available in Malta for the treatment of severe asthma. METHODS This study aims to evaluate the symptomatology and disease course of SARS-CoV-2 in our cohort of severe asthmatic patients on omalizumab that contracted COVID-19. Molecular diagnostic tests (SARS-CoV-2 PCR tests taken, if any, and the PCR result) since March 2020 of all adult patients receiving omalizumab for severe allergic asthma in January 2021, were reviewed from I-soft Clinical Manager®. Demographic data were collected for those patients who were found to be positive. RESULTS Our cohort included 58 patients, of whom 43 had PCR tests. Of these, 7 patients (12%) tested positive during the study period. Results show a male predominance in the cohort, with fever being the commonest symptom, and a mortality of only 1 patient out of 7. CONCLUSIONS From the small number of our severe asthmatic patients infected with SARS-CoV-2 whilst receiving omalizumab, the majority had only mild symptoms, with minimal effect on asthma-related symptoms and hospitalizations, apart from mortality in one patient.

show abstract

“…Per pirmąją SARS-CoV-2 pandemijos bangą daugelis autorių, nacionalinės ir tarptautinės mokslo draugijos paskelbė savo rekomendacijas dėl astma sergančių sunkių pacientų gydymo ir biologinių vaistų vartoji mo. Dauguma pulmonologų ir alergologų ir klinikinių imunologų draugijų, gydymo gairių rekomenduoja tęsti pacientui įprastą astmos gydymą, įskaitant biologinius vaistus, kuriems šis gydymas buvo taikomas iki suser gant COVID-19 [49][50][51][52], jeigu buvo nustatytas gydo masis poveikis, tačiau naujai skirti COVID-19 metu nerekomenduojama. Amerikos alergijos, astmos ir imunologijos akademija (AAAAI) nurodo, kad turimais duomenimis, gydymas monokloniniais antikūnais ne pakeičia imuninio atsako, susirgus COVID-19 [53,54].…”

Section: Sunki Astma Ir Biologinė Terapijaunclassified

Sunki astma ir COVID-19

Kalinauskaitė-Žukauskė

2021

PIA

View full text Add to dashboard Cite

Sergančiajam sunkia astma reikalinga specializuota pagalba. Pandemijos akistatoje baiminamasi, kad sunkia astma sergantys asmenys greičiau susirgs COVID–19 arba jos eiga komplikuosis. Atliktų tyrimų duomenys rodo, kad susirgimų arba komplikacijų dažnis nesiskiria nuo bendrosios populiacijos, jei užtikrinama gera astmos simptomų kontrolė ir nėra nuolatinio geriamųjų gliukokortikoidų vartojimo. Daug abejonių būta ir dėl biologinių vaistų skyrimo pandemijos laikotarpiu, tačiau esama patirtis ir atliktų tyrimų duomenys rodo, kad netgi susirgus COVID–19, biologinė terapija turi būti tęsiama, nors pradėti nerekomenduojama. Atskiras daug diskusijų sukėlęs klausimas – vakcinacija. Vis tik kol kas tai vienas veiksmingiausių būdų valdyti pandemijai ir grįžti į kasdienį gyvenimą, buvusį iki pandemijos.

show abstract

Severe asthma and COVID-19: lessons from the first wave

Cited by 10 publications

References 25 publications

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

Sunki astma ir COVID-19

Contact Info

Product

Resources

About